RightFit
RecruitingPhase 3

A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease

A Phase III, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once Weekly Petrelintide Vs. Placebo in Participants With Overweight Or Obesity And Established Cardiovascular Disease

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
40 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests how well petrelintide helps with weight loss and how safe it is compared with a placebo (a treatment with no active drug). It is for people with overweight or obesity who have heart or blood vessel disease. Both groups will also follow a lower-calorie diet and increase physical activity.

This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity and established cardiovascular disease (CVD).

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Have a BMI of 27 or higher. BMI is a measure of weight compared with height.
  • Have heart or blood vessel disease.
  • Report trying at least one diet to lose weight that did not work.

Who can't join

  • Have a known history of type 1 diabetes.
  • Take or have ever taken petrelintide or another amylin analog (a drug that acts like the hormone amylin).

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Participants with BMI ≥ 27 kg/m² and established CVD * History of at least one self-reported unsuccessful dietary effort to lose body weight Exclusion Criteria: * Known history of Type 1 diabetes mellitus * Current or previous treatment with petrelintide or any other amylin analog

Study sites (3)

AL

CA

FL